NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that ...

Staphylococcus aureus is a major human pathogen responsible for a wide diversity of infections ranging from localized to life threatening diseases. From 1961 and the emergence of methicillin-resistant ...

As part of the study, researchers tested and genetically analyzed 73 different hospital-acquired and community-acquired strains of the MRSA microbe. They then treated the various MRSA bugs in test ...

Using rapid molecular diagnostic testing for multidrug-resistant bacteria among patients with purulent skin infections did not reduce inappropriate antibiotic prescription of MRSA antibiotics for ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

Chemists from the University of Warwick and Monash University have discovered a promising new antibiotic that shows activity against drug-resistant bacterial pathogens, including MRSA and VRE ...

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main causes of both community-acquired and hospital-acquired infections and has become resistant to almost all known available ...

The prevalence of antimicrobial resistance (AMR) varies significantly among different patient populations. We aimed to summarise AMR prevalence data from screening studies in different patient ...